Alzheimer's Disease ACE Simulator

Comprehensive, extensively documented, multi-application model designed to support commercial strategy development, inform clinical trial designs, and meet HTA requirements for formal submissions in Alzheimer's disease (AD).

- Assesses interventions from the earliest (i.e., mild cognitive impairment or prodromal AD) through the most severe stages of disease, as well as the transition from normal cognitive function.
- Addresses the complex interactions between multiple components of AD pathology (e.g., biomarkers, cognition, behavior, function) and their roles in disease progression.
- Fully considers interrelated clinical, epidemiologic, and economic outcomes, providing a platform that allows for rapid incorporation of intervention-specific data.
- Programmed in MS Excel®, it does not require any additional software, is very transparent, and may be readily modified to address the specific features of the therapy or diagnostic that is being studied.



Our Team & EXPERIENCE

— 15+ —

Years of experience supporting modeling needs of numerous cholinesterase inhibitors and other Alzheimer's disease products

— 50+ —

Peer-reviewed publications and presentations on Alzheimer's disease and mild cognitive impairment (MCI)

— 400+ —

Health and economic models developed across all therapeutic areas for countries around the globe

— 70+ —

Research projects in Alzheimer's disease, with 20+ in economic modeling since 2010

What Makes Us UNIQUE

— Expertise —

Developed the AHEAD[1] and AHEAD II models, which are among the most cited dementia models, and have been instrumental in securing positive reimbursement decisions from numerous agencies, including NICE

— Innovative —

Introduced discrete event simulation (DES) to the field in 2000; still at the forefront of modeling methods, e.g., discretely integrated condition event (DICE) simulation, MCDA, clinical trial simulation

— Leaders —

Numerous industry leadership roles, e.g., ISPOR-SMDM Task Force, ISPOR MCDA Task Force, and ISPOR Oncology Special Interest Group

— Influence —

Evidera's modeling and simulation team has supported submissions to NICE, CADTH, IQWiG, FDA, PBAC, and others

> "Your commitment to conducting quality research, knowledge of state-of-the-art methodologies, attention to detail and flexibility in the research process all combine to produce important and credible findings. Add collegiality and good cheer and the combination is quite impressive."
>
> Director, Health Economics and Outcomes Research, Top 10 Pharmaceutical Company

[1] AHEAD = Assessment of Health Economics in Alzheimer's Disease